The Saudi Food and Drug Authority (SFDA) has granted PTC Therapeutics orphan drug designation to Sephience (sepiapterin), which is indicated for the treatment of hyperphenylalaninaemia (HPA) in patients with phenylketonuria (PKU).
Registration is Subjected to Full Scientific Evaluation
The Saudi Food and Drug Authority (SFDA) has signed a Memorandum of Cooperation (MoC) with the Food Industries Polytechnic (FIP) to strengthen collaboration in the training and qualification of national cadres, focusing on building specialized human capital in fields shared by both organizations.
The Kingdom of Saudi Arabia, represented by the Saudi Food and Drug Authority (SFDA), has further solidified its international scientific standing by officially joining the Joint FAO/WHO Expert Committee on Food Additives (JECFA).
The Saudi Food and Drug Authority (SFDA) recorded significant growth in the number of licensed factories and warehouses during 2025, achieving a 18% increase compared to 2024. This growth reflects the ongoing development of the regulatory environment, the empowerment of the industrial sector, and the expansion of investment support within the SFDA’s scope of work.
According to official statistics, the total number of licensed facilities reached 9,155 in 2025, up from 7,750 in 2024.
The Saudi Food and Drug Authority (SFDA) successfully concluded its international Codex Alimentarius Workshop, held at its headquarters in Riyadh from January 20–22, under the theme “One Codex: Together We Learn, Together We Lead.”
The workshop featured the participation of the Chairperson of the Codex Alimentarius Commission (CAC) and his Vice-Chairs, Codex regional coordinators, the Codex Secretariat, and representatives from the Food and Agriculture Organization of the United Nations (FAO) and the World Health Organization (WHO).
A delegation from the Codex Alimentarius Commission (CAC), headed by its Chairperson, Allan Azegele, visited the Saudi Food and Drug Authority (SFDA)’s Interactive Awareness Center. The visit took place during the delegation’s trip to the Kingdom of Saudi Arabia on the sidelines of an international workshop held by SFDA in Riyadh.
The Saudi Food and Drug Authority (SFDA) is hosting an international Codex Alimentarius Workshop at its headquarters in Riyadh. Held from January 20 to 22, 2026, under the theme “one Codex: Together We Learn, Together We Lead,” the event brings together the world’s foremost experts in food safety and regulation.
Warning Status
|
|
|---|---|
Warning Date
|
|
Manufacture Company
|
|
The Saudi Food and Drug Authority (SFDA) has issued a warning regarding specific infant formula products produced by Nestlé under the NAN, ALFAMINO, S-26 GOLD, and S-26 ULTIMA brands. This warning follows a voluntary notification from the company concerning a recall of several product batches due to potential contamination with cereulide, a toxin produced by Bacillus cereus bacteria, which may pose a risk to infants’ health.
To report sector-related issues
Call Centre 19999
As part of its Fourth Strategic Plan (2023–2027), the Saudi Food and Drug Authority (SFDA) is building a comprehensive regulatory ecosystem to advance food innovation and biotechnology in Saudi Arabia. The Authority focuses on developing legislation and control systems for emerging biotech products, supporting research and innovation, and promoting national initiatives that position the Kingdom at the forefront of the global transition towards modern and sustainable food production systems.
